Xcout Intel
Artax Biopharma, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Artax Biopharma, Inc. among biotechnology companies — ranked by similarity to what Artax Biopharma, Inc. actually does, not by market-cap band.
Subscribe to see Artax Biopharma, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Artax Biopharma, Inc.
Artax Biopharma, Inc. is a clinical-stage biotechnology company founded in 2013 and headquartered in Cambridge, Massachusetts. The company is focused on transforming the treatment of immune system diseases and recently raised $8 million ahead of a Phase 2a clinical trial.
Artax Biopharma, Inc. at a glance
Artax Biopharma, Inc. is a biotechnology company headquartered in United States. Its most recent funding round raised $8M in July 2024. Xcout tracks 16 named people at Artax Biopharma, Inc., including Rob Armstrong (Chief Executive Officer).
Artax Biopharma, Inc. leadership
- Rob ArmstrongChief Executive Officer
- Robert Armstrong, Ph.D.President & Chief Executive Officer
- Andy GageteChief Operating Officer
- Joe SuarezChief Financial Officer
- Chris VanDeusenChief Scientific Officer
- D. Scott Batty, Jr.Chief Medical Officer
10 more named people on record for Artax Biopharma, Inc., with roles, board committees and tenure — see the full roster →
Artax Biopharma, Inc. funding rounds
The 4 most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $8M | 7 named | |
| — | $19M | 7 named | |
| — | Undisclosed | 6 named | |
| SEC Form D filing | $25.8M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Artax Biopharma, Inc. competitors
Ranked by semantic similarity — how close each company is to Artax Biopharma, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Ankyra Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2019 and headquartered in Cambridge, Massachusetts. The enterprise specializes in developing proprietary anchored cytokine therapies designed to treat various cancers and immune diseases. Its platform technology localizes immune-stimulatory treatments within tumors to maximize therapeutic efficacy while minimizing systemic toxicity.
Similar biotechnology company
Apogee Therapeutics is a biotechnology company focused on the development of therapies for inflammatory and immunology diseases. The company is headquartered in Waltham, Massachusetts.
Biotech
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
Similar biotechnology company
Immunitas Therapeutics, Inc. is a US-based biotechnology company established in 2019 and headquartered in Waltham, Massachusetts. The company focuses on pioneering novel therapeutic treatments in immunology and oncology.
Biotech
HiFiBio Therapeutics is a clinical-stage immune modulation biotechnology company headquartered in Cambridge, Massachusetts. The company focuses on discovering and developing novel precision antibody therapeutics for immunology and oncology applications.
Similar biotechnology company
Abcuro, Inc. is a biotechnology company headquartered in Newton, Massachusetts, focused on developing advanced immunotherapies to treat autoimmune diseases and cancer.
Similar biotechnology company
Q32 Bio Inc. is a clinical-stage biotechnology company, headquartered in Waltham, Massachusetts, focused on creating innovative biologic treatments. Operating within the United States, its primary objective is to re-establish a healthy immune balance in individuals suffering from autoimmune and inflammatory conditions stemming from pathological immune dysfunction. The company's primary therapeutic candidate, ADX-097, is a humanized monoclonal antibody fusion protein engineered to restore proper complement regulation. This compound has successfully concluded its Phase I clinical trial and is being advanced for the treatment of severe renal and other complement-mediated diseases that present significant unmet medical needs. These include specific conditions like lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. Furthermore, Q32 Bio is progressing Bempikibart (ADX-914), a fully human monoclonal antibody that functions as an interleukin-7 receptor alpha antagonist. By disrupting the signaling pathways mediated by interleukin-7 and thymic stromal lymphopoietin, Bempikibart aims to normalize adaptive immune function. This promising candidate is currently undergoing Phase II clinical trials for the management of atopic dermatitis and alopecia areata. The company, established in 2017, was previously known as AdMIRx Inc. and rebranded to Q32 Bio Inc. in April 2020.
Similar biotechnology company
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and autoimmune diseases. Headquartered in California, the company advances a robust clinical pipeline and operates as a publicly traded enterprise.
Similar biotechnology company
Third Arc Bio, Inc. is a clinical-stage biotechnology company founded in 2022 and based in Ambler, Pennsylvania, dedicated to developing multifunctional antibodies optimized for best-in-class therapies.
Similar biotechnology company
CREATE Medicines is a clinical-stage biotechnology company located in Cambridge, Massachusetts, pioneering in vivo immune programming with RNA.
Similar biotechnology company
Be Biopharma is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing engineered B cell therapies.
Life Sciences
Poplar Therapeutics is a biotechnology company focused on creating the next generation of anti-IgE medicines to treat patients. Headquartered in Cambridge, Massachusetts, the early-stage startup develops novel therapeutics to help patients live free of fear from allergic and immune conditions.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Artax Biopharma, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Artax Biopharma, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →